Tirzepatide vs Semaglutide: Head-to-Head Data (2026)
Quick answer
Tirzepatide outperformed semaglutide in every head-to-head measure. In the SURMOUNT-5 trial, tirzepatide produced 20.2% body weight loss vs 13.7% for semaglutide over 72 weeks. Tirzepatide works on both GLP-1 and GIP receptors, while semaglutide targets GLP-1 only.
Side-by-side comparison
| Tirzepatide | Semaglutide | |
|---|---|---|
| Mechanism | Dual GIP/GLP-1 receptor agonist | GLP-1 receptor agonist only |
| Avg weight loss | 20.2% body weight (SURMOUNT-5) | 13.7% body weight (SURMOUNT-5) |
| Brand names | Mounjaro, Zepbound | Ozempic, Wegovy |
| Dosing | Once weekly injection | Once weekly injection |
| Common side effects | Nausea, diarrhea (mild, decreasing over time) | Nausea, diarrhea (mild, decreasing over time) |
| LYV compounded price | From $197/mo | Not currently offered |
| Brand-name cost | $1,000-1,200/mo without insurance | $1,000-1,350/mo without insurance |
| Timeline to results | Appetite changes week 1, 10-15 lbs by month 3 | Appetite changes week 1-2, 8-12 lbs by month 3 |
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved as Mounjaro (diabetes) and Zepbound (weight management). It mimics two gut hormones -- GIP and GLP-1 -- that reduce hunger, slow gastric emptying, and improve insulin sensitivity. The dual mechanism is what separates it from older GLP-1-only drugs. In the SURMOUNT-1 trial (n=2,539), participants lost an average of 22.5% of their body weight at the highest dose over 72 weeks. The FDA approved it for chronic weight management in November 2023.
Semaglutide
Semaglutide is a GLP-1 receptor agonist sold as Ozempic (diabetes) and Wegovy (weight management). It was the first modern GLP-1 to gain widespread adoption for weight loss. In the STEP 1 trial (n=1,961), participants lost an average of 14.9% of body weight over 68 weeks. Semaglutide targets GLP-1 receptors only and is administered as a once-weekly injection. It has been on the market longer and has a broader evidence base across cardiovascular outcomes.
Key differences
- •Tirzepatide targets two receptors (GIP + GLP-1) vs semaglutide's one (GLP-1 only), which drives the additional weight loss.
- •In the head-to-head SURMOUNT-5 trial, tirzepatide produced 47% more weight loss than semaglutide over the same 72-week period.
- •Both have similar side effect profiles (mostly GI-related), though tirzepatide's dual mechanism may improve insulin sensitivity more than semaglutide alone.
- •Semaglutide has more published cardiovascular outcome data (SELECT trial) showing a 20% reduction in major cardiovascular events.
- •Compounded tirzepatide through LYV costs roughly 80% less than the brand-name versions of either drug.
Which should you choose?
Tirzepatide
Choose tirzepatide if maximizing weight loss is your primary goal. The clinical data is clear -- it produces significantly more fat loss than semaglutide. It is also the better option if you have insulin resistance or pre-diabetes, since the dual GIP mechanism directly improves insulin sensitivity.
Semaglutide
Semaglutide may be worth considering if you have specific cardiovascular risk factors and your provider recommends it based on the SELECT trial data. It also has a longer track record on the market. However, for pure weight loss efficacy, tirzepatide is the stronger option.
Frequently asked questions
Is tirzepatide really 47% more effective than semaglutide?
Yes. The SURMOUNT-5 trial directly compared tirzepatide and semaglutide in the same study population over 72 weeks. Tirzepatide produced 20.2% body weight loss vs 13.7% for semaglutide. That is a 47% relative difference. This was published in the New England Journal of Medicine.
Why does LYV offer tirzepatide but not semaglutide?
LYV focuses on the compounds with the strongest clinical evidence for each goal. For weight loss, tirzepatide outperforms semaglutide in every head-to-head measure. We prescribe the compound that gives you the best chance of reaching your goal.
Are the side effects different between tirzepatide and semaglutide?
The side effect profiles are very similar. Both cause nausea, diarrhea, and reduced appetite -- primarily in the first 2-4 weeks and during dose increases. These are typically mild and decrease over time. There is no clinically significant difference in side effect rates between the two.
Can I switch from semaglutide to tirzepatide?
Yes. Many providers transition patients from semaglutide to tirzepatide. Your prescribing provider determines the appropriate starting dose based on your current semaglutide dose and response. There is typically no washout period needed.
Is compounded tirzepatide the same as Mounjaro or Zepbound?
Compounded tirzepatide contains the same active molecule. It is prepared by a licensed US compounding pharmacy under FDA oversight. The difference is that it is not manufactured by Eli Lilly and does not carry the Mounjaro or Zepbound brand name. The clinical compound is identical.
Ready to see which option fits your goals?
Take a 2-minute quiz. Get a personalized protocol.